Hepatitis C in African Americans: Summary of a workshop

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1385-1396

  Howell, Charles ^a   Jeffers, Lennox ^b   Hoofnagle, Jay H ^c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

AFRICAN AMERICAN; HEPATITIS C; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; STATISTICS; SUBSTANCE ABUSE; UNITED STATES; VETERAN; VIROLOGY;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PREVALENCE; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; VETERANS;

EID: 0034320232     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19582     Document Type: Article

References (40)

1. Alter MJ, Kruszon-Morar D, Nainan 0V, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Mnrgolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-E62.
2. Navarro VJ, Heye CJ, Kunze KB, Ivie KB, Terrault NA, Manos MM, Alter MJ, Bell BP. Sentinel surveillance for chronic liver disease: the New Haven County Liver Study [abstr], Hepatology 1999;30: 478A.
3. Seaberg EC, Belle SH, Eeringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. In: Cecka JM, Terasaki PI, eds. Clinical transplants 1998. Los Angeles, California, UCLA Tissue Typing Laboratory, 1998:17-37.
4. Man RE, Smart RG, Anjjlin L, Adlaf EM. Reductions in cirrhosis deaths in the United States: associations with per capita consumption and AA membership. J Stud Alcohol 1991;52:361365.
5. El Serag HB, Mason A. Rising incidence of hepatocellular carcinoma in the United Stares. N Engl J Med 1999:340:745-750.
6. ReddyKR, Hoofnagle JH.TongMJ, Lee WM, Pockros P, Heathcote EJ, Albert D, John T, foi the Consensus Interferon Study Group. Racial differences in response to therapy with Interferon in chronic hepatitis C. Hepatology 1999:30:787-793.
7. Alter MJ, Gallagher M, Morris TT, Moyer LA, Meeks EL, Krawczynski K, Kim JP, Margolis HS. Acute non-A-E hepatitis in the United States and the role of lepatitis G virus infection. N Engl J Med 1997:336:741-746.
8. Frieden TR, Ozick L, McCord C, Nainan 0V, Workman S, Comer G, Lee TP, Buyn K-S, Patel D, Henning KJ. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 1999;29:883-888.
9. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999:341:866-870.
10. Kenny-Walsh E, Irish Hepatology Research Group. Clinical outcome after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999:340:1228-1233.
11. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG, National Heart, Lung and Blood Institute Study Group. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Eng J Med 1992:327:1906-1911.
12. Tong MJ, EI-Farra NS, Reikes A, Co RL. Clinical outcomes after transfusion-associatec hepatitis C. N Engl J Med 1995:332: 1463-1466.
13. McHutchison JG, Poynard T, Gordon SC, Dienstag J, Morgan T, Yao R, Ling MH, Cort S, Garaud JJ, Albrecht J. The impact of race on response to anti-viml therapy in patients with chronic hepatitis C [abstr]. Hepatology L999;30:302A.
14. Wiley TE, Mika BP, McCarthy ME, Layden TJ. Pre-treatment differences between HCV-infected African American and non-African American patients [abstr]. Hepatology 1999;30:417A.
15. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832.
16. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
17. Ray SC, Wang Y-M, Laeyendecker 0, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999;73:2938-2946.
18. Pham D, Walshe D, Montgomery J, Buskell-Bales Z, Collier K, Lokken G, Claggett J, Wilson L, Biswas R, Gibert C, Seeff LB. Seroepidemiology of hepatitis B and C in an urban VA medical center [abstr]. Hepatology 1994;24:236A.
19. Mitchell T, Holohan TV, Wright TL, Kizer KW. At war with hepatitis C, Part 1: the VA's strategic initiative. Fed Pract 1999;16:14-17.
20. Staples CT Jr, Rimland DV, Dudas D. Hepatitis C in the human immuno-deficiency virus Atlanta Veterans Affairs Medical Center Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999:29:150-154.
21. Ferenci P, Dragosics B, Marosi L, Kiss F. Relative incidence of primary liver cancer in cirrhosis in Austria: aetiological considerations. Liver 1984;4:7-14.
22. Zaman SN Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985:1:1357-1360.
23. Hasan F, Jeffers U, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo Q, Kuo G. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591.
24. Di Bisceglie AM, Klein J, Choo Q, Kuo G, Houghton M, Sjogren M, Order SE. Role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86:335-338.
25. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Meeting Report. Hepatology 1998:28:1161-1165.
26. Di Bisceglie AM, Schwartz M, Reddy R, Martin P, Gores GJ, Hussein K, Gish RG, Van Thiel DH, Younossi ZM, Tong MJ, Hassanein Tl, Baiart L, Fleckenstein JF. Hepatitis C and hepatocellular carcinoma in African Americans (abstr). Gastroenterology 2000;118:A1435.
27. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle JH. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-830.
28. Lau D-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis B treated with Interferon a. Gastroenterology 1997;113: 1660-1667.
29. Shiftman M, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Fried MW, Purdum PP III, Everson G, Pedder S and pegylated interferonalfa-2a Clinical Study Group. A controlled, randomized, multicenter, descending dose, phase II trial of pegylated Interferon alfa-2a (PEG) vs standard Interferon alfa-2a (IFN) for treatment of chronic hepatitis C [abstr]. Gastroenterology 1999;116:L418 .
30. Heathcote EJ, Shiftman ML, Cooksley G, Dusheiko GM, Lee SS, Baiart L, Reindollar R, Reddy R, Wright T, Dephamphilis J. Multinational evaluation of the efficacy and safety of once weekly peginterferon a2A in patients with chronic hepatitis C with compensated cirrhosis [abstr]. Hepatology 1999;30:316A.
31. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albrecht JK, for the Hepatitis Inverventional Study Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998:339:1485-1492.
32. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-1432.
33. Flechenstein JF, Ismail MK, Bockhold K, Van Leeuwen D, Riely CA, Waters B, South Central Liver Study Group. African American response rate to therapy for hepatitis C [abstr]. Hepatology 1998;28:283A.
34. Brass CA, US Rebetron Investigators. Are African Americans with chronic HCV more resistant to antiviral therapy [abstr]? Hepatology 1999;30:270A.
35. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon-a therapy. Science 1998:282:103-107.
36. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996;271:1582-1586.
37. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
38. Sherman K, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999:30:265-170.
39. Baquet CR, Marconi K, Alexander G. Moving from health care research to action. Henry Ford Hosp Med J 1992;40:66-70.
40. Gale MJ, Korth M, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clini Diagn Virol 1998;10:157162.